Sylvia J Gasparini1, Michael M Swarbrick1, Sarah Kim1, Lee J Thai1, Holger Henneicke1,2,3,4, Lauryn L Cavanagh1, Jinwen Tu1, Marie-Christin Weber1,5, Hong Zhou1,6, Markus J Seibel7,8. 1. Bone Research Program, ANZAC Research Institute, The University of Sydney, Gate 3, Hospital Road, Concord, NSW, 2139, Australia. 2. Department of Medicine III, Technische Universität Dresden Medical Center, Dresden, Germany. 3. Center for Healthy Aging, Technische Universität Dresden Medical Center, Dresden, Germany. 4. Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany. 5. Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany. 6. Concord Medical School, The University of Sydney, Sydney, Australia. 7. Bone Research Program, ANZAC Research Institute, The University of Sydney, Gate 3, Hospital Road, Concord, NSW, 2139, Australia. markus.seibel@sydney.edu.au. 8. Concord Medical School, The University of Sydney, Sydney, Australia. markus.seibel@sydney.edu.au.
Abstract
AIMS/HYPOTHESIS: Chronic glucocorticoid therapy causes insulin resistance, dyslipidaemia, abnormal fat accumulation, loss of muscle mass and osteoporosis. Here we describe a hitherto unknown sexual dimorphism in the metabolic response to chronic glucocorticoid exposure in mice. This led us to investigate whether glucocorticoid-induced insulin resistance and obesity were dependent on sex hormones. METHODS: Male and female CD1 mice were treated for 4 weeks with supraphysiological doses (~250 μg/day) of corticosterone, the main glucocorticoid in rodents, or equivalent volume of vehicle (drinking water without corticosterone). To investigate the effects of sex hormones, a separate group of mice were either orchidectomised or ovariectomised prior to corticosterone treatment, with or without dihydrotestosterone replacement. Body composition was determined before and after corticosterone treatment, and insulin tolerance was assessed after 7 and 28 days of treatment. Adipocyte morphology was assessed in white and brown adipose tissues by immunohistochemistry, and fasting serum concentrations of NEFA, triacylglycerols, total cholesterol and free glycerol were measured using colorimetric assays. Obesity- and diabetes-related hormones were measured using multiplex assays, and RNA and protein expression in adipose tissues were measured by RT-PCR and immunoblotting, respectively. RESULTS: Chronic corticosterone treatment led to insulin resistance, fasting hyperinsulinaemia, increased adiposity and dyslipidaemia in male, but not female mice. In males, orchidectomy improved baseline insulin sensitivity and attenuated corticosterone-induced insulin resistance, but did not prevent fat accumulation. In androgen-deficient mice (orchidectomised males, and intact and ovariectomised females) treated with dihydrotestosterone, corticosterone treatment led to insulin resistance and dyslipidaemia. In brown adipose tissue, androgens were required for corticosterone-induced intracellular lipid accumulation ('whitening'), and dihydrotestosterone specifically exacerbated corticosterone-induced accumulation of white adipose tissue by increasing adipocyte hypertrophy. Androgens also suppressed circulating adiponectin concentrations, but corticosterone-induced insulin resistance did not involve additional suppression of adiponectin levels. In white adipose tissue, androgens were required for induction of the glucocorticoid target gene Gilz (also known as Tsc22d3) by corticosterone. CONCLUSIONS/ INTERPRETATION: In mice, androgens potentiate the development of insulin resistance, fat accumulation and brown adipose tissue whitening following chronic glucocorticoid treatment.
AIMS/HYPOTHESIS: Chronic glucocorticoid therapy causes insulin resistance, dyslipidaemia, abnormal fat accumulation, loss of muscle mass and osteoporosis. Here we describe a hitherto unknown sexual dimorphism in the metabolic response to chronic glucocorticoid exposure in mice. This led us to investigate whether glucocorticoid-induced insulin resistance and obesity were dependent on sex hormones. METHODS: Male and female CD1mice were treated for 4 weeks with supraphysiological doses (~250 μg/day) of corticosterone, the main glucocorticoid in rodents, or equivalent volume of vehicle (drinking water without corticosterone). To investigate the effects of sex hormones, a separate group of mice were either orchidectomised or ovariectomised prior to corticosterone treatment, with or without dihydrotestosterone replacement. Body composition was determined before and after corticosterone treatment, and insulin tolerance was assessed after 7 and 28 days of treatment. Adipocyte morphology was assessed in white and brown adipose tissues by immunohistochemistry, and fasting serum concentrations of NEFA, triacylglycerols, total cholesterol and free glycerol were measured using colorimetric assays. Obesity- and diabetes-related hormones were measured using multiplex assays, and RNA and protein expression in adipose tissues were measured by RT-PCR and immunoblotting, respectively. RESULTS: Chronic corticosterone treatment led to insulin resistance, fasting hyperinsulinaemia, increased adiposity and dyslipidaemia in male, but not female mice. In males, orchidectomy improved baseline insulin sensitivity and attenuated corticosterone-induced insulin resistance, but did not prevent fat accumulation. In androgen-deficient mice (orchidectomised males, and intact and ovariectomised females) treated with dihydrotestosterone, corticosterone treatment led to insulin resistance and dyslipidaemia. In brown adipose tissue, androgens were required for corticosterone-induced intracellular lipid accumulation ('whitening'), and dihydrotestosterone specifically exacerbated corticosterone-induced accumulation of white adipose tissue by increasing adipocyte hypertrophy. Androgens also suppressed circulating adiponectin concentrations, but corticosterone-induced insulin resistance did not involve additional suppression of adiponectin levels. In white adipose tissue, androgens were required for induction of the glucocorticoid target gene Gilz (also known as Tsc22d3) by corticosterone. CONCLUSIONS/ INTERPRETATION: In mice, androgens potentiate the development of insulin resistance, fat accumulation and brown adipose tissue whitening following chronic glucocorticoid treatment.
Authors: Chase H Bourke; Madiha Q Raees; Sanjana Malviya; Cory A Bradburn; Elisabeth B Binder; Gretchen N Neigh Journal: Psychoneuroendocrinology Date: 2012-05-29 Impact factor: 4.905
Authors: Timo D Müller; Sang Jun Lee; Martin Jastroch; Dhiraj Kabra; Kerstin Stemmer; Michaela Aichler; Bill Abplanalp; Gayathri Ananthakrishnan; Nakul Bhardwaj; Sheila Collins; Senad Divanovic; Max Endele; Brian Finan; Yuanqing Gao; Kirk M Habegger; Jazzmin Hembree; Kristy M Heppner; Susanna Hofmann; Jenna Holland; Daniela Küchler; Maria Kutschke; Radha Krishna; Maarit Lehti; Rebecca Oelkrug; Nickki Ottaway; Diego Perez-Tilve; Christine Raver; Axel K Walch; Sonja C Schriever; John Speakman; Yu-Hua Tseng; Maria Diaz-Meco; Paul T Pfluger; Jorge Moscat; Matthias H Tschöp Journal: J Clin Invest Date: 2012-12-21 Impact factor: 14.808
Authors: Sheng Li; Milena Schönke; Jacobus C Buurstede; Tijmen J A Moll; Max Gentenaar; Maaike Schilperoort; Jenny A Visser; Kasiphak Kaikaew; Davy van de Vijver; Tooba Abbassi-Daloii; Vered Raz; Annemieke Aartsma-Rus; Maaike van Putten; Onno C Meijer; Jan Kroon Journal: Front Endocrinol (Lausanne) Date: 2022-07-11 Impact factor: 6.055
Authors: Erika Harno; Charlotte Sefton; Jonathan R Wray; Tiffany-Jayne Allen; Alison Davies; Anthony P Coll; Anne White Journal: Sci Rep Date: 2021-07-02 Impact factor: 4.379